Rabia A. Gilani, Ph.D.
Affiliations: | 2011 | Toxicology | University of Maryland School of Medicine, Baltimore, MD, United States |
Area:
Molecular Biology, BiochemistryGoogle:
"Rabia Gilani"Mean distance: (not calculated yet)
Parents
Sign in to add mentorAngela H. Brodie | grad student | 2011 | University of Maryland Medical School | |
(Role of Lapatinib and Retinoids In Overcoming Intrinsic Resistance to Hormonal Therapy In Breast Cancer.) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Gilani RA, Phadke S, Bao LW, et al. (2020) Retraction: UM-164: A Potent c-Src/p38 Kinase Inhibitor with Activity against Triple-Negative Breast Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 26: 1777 |
Kaushal N, Tiruchinapally G, Durmaz YY, et al. (2018) Synergistic inhibition of aggressive breast cancer cell migration and invasion by cytoplasmic delivery of anti-RhoC silencing RNA and presentation of EPPT1 peptide on "smart" particles. Journal of Controlled Release : Official Journal of the Controlled Release Society |
Jiagge E, Bensenhaver J, Celina K, et al. (2018) Creating Models to Identify New Therapeutic Options for Aggressive African Breast Cancers Journal of Global Oncology. 4: 206s-206s |
Gilani R, Lachacz E, Bao LW, et al. (2018) Rational drug combination therapy for improved efficacy and delayed resistance in triple negative breast cancer. Journal of Clinical Oncology. 36: e13113-e13113 |
Caceres S, Little AC, Yates JA, et al. (2018) Abstract 2044: Lymphatic vessel endothelial hyaluronan receptor-1 (LYVE-1) modulates VEGF-C and VEGF-D secretion in the triple negative breast cancer cell line MDA-MB-231 Tumor Biology |
Gilani RA, Lachacz EJ, Phadke S, et al. (2017) Abstract 4117: Mechanisms of acquired resistance to c-Src kinase inhibitor in triple negative breast cancer Cancer Research. 77: 4117-4117 |
Kazi AA, Gilani RA, Schech AJ, et al. (2014) Nonhypoxic regulation and role of hypoxia-inducible factor 1 in aromatase inhibitor resistant breast cancer. Breast Cancer Research : Bcr. 16: R15 |
Schech AJ, Kazi AA, Gilani RA, et al. (2013) Zoledronic acid reverses the epithelial-mesenchymal transition and inhibits self-renewal of breast cancer cells through inactivation of NF-κB. Molecular Cancer Therapeutics. 12: 1356-66 |
Shah P, Sabnis GJ, Goloubeva O, et al. (2013) Abstract 1311: Preclinical assessment of an HDAC inhibitor combined with a retinoid in AI resistant breast cancer. Cancer Research. 73: 1311-1311 |
Gilani RA, Kazi AA, Shah P, et al. (2012) The importance of HER2 signaling in the tumor-initiating cell population in aromatase inhibitor-resistant breast cancer. Breast Cancer Research and Treatment. 135: 681-92 |